somatostatin receptor positive tumour
Showing 1 - 25 of >10,000
Neuroendocrine Carcinoma Trial in London (Lu-DOTA-TATE)
Active, not recruiting
- Neuroendocrine Carcinoma
- Lu-DOTA-TATE
-
London, Ontario, CanadaLondon Health Sciences Centre
Apr 5, 2022
Breast Cancer Stage IV Trial in Irvine (Gallium-68)
Recruiting
- Breast Cancer Stage IV
-
Irvine, CaliforniaHoag Memorial Hospital Presbyterian
May 26, 2023
Neuroendocrine Tumors Trial in Beijing (Lutetium[177Lu] Oxodotreotide Injection)
Not yet recruiting
- Neuroendocrine Tumors
- Lutetium[177Lu] Oxodotreotide Injection
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
May 30, 2023
Neuroendocrine Tumors, Carcinoid Tumor, Pulmonary Carcinoid Tumor Trial in Vancouver (177Lu-DOTATOC)
Not yet recruiting
- Neuroendocrine Tumors
- +6 more
-
Vancouver, British Columbia, CanadaBC Cancer
Aug 19, 2022
Lutathera® in Somatostatin Receptor Positive
Recruiting
- Somatostatin Receptor-positive GEP-NET
- Lutathera
-
Seongnam Si, Gyeonggi Do, Korea, Republic of
- +4 more
Jun 29, 2022
Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour Trial in Worldwide (Octreotide LAR, 177Lu-DOTA0-Tyr3-Octreotate)
Completed
- Carcinoid Tumor of the Small Bowel
- Neuroendocrine Tumour
- Octreotide LAR
- 177Lu-DOTA0-Tyr3-Octreotate
-
Los Angeles, California
- +38 more
Mar 10, 2022
68-Ga DOTATATE PET/MRI in Diagnosis and Management of
Recruiting
- CNS Tumors
- +6 more
- Ga68-DOTATATE-PET/MRI
-
New York, New YorkWeill Cornell Medicine
Sep 20, 2022
Neuroendocrine Tumors Trial in Edmonton (68Ga-HA-DOTATATE)
Recruiting
- Neuroendocrine Tumors
-
Edmonton, Alberta, CanadaUniversity of Alberta
Apr 11, 2022
Neuroendocrine Tumors, Meningioma, Neuroblastoma Trial in Iowa City (radiation, diagnostic test, drug)
Active, not recruiting
- Neuroendocrine Tumors
- +3 more
- 90Y-DOTA tyr3-Octreotide
- +2 more
-
Iowa City, IowaUniversity of Iowa Hospitals and Clinics
Oct 6, 2022
Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) Trial in Basel (161Tb-DOTA-LM3,
Not yet recruiting
- Neuroendocrine Neoplasia's (NENs)
- Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
-
Basel, SwitzerlandDivision of Nuclear Medicine, University Hospital Basel
Apr 27, 2022
Neuroendocrine Tumors Trial in Portland (Cabozantinib, Lu-177)
Not yet recruiting
- Neuroendocrine Tumors
-
Portland, OregonProvidence Portland Cancer Institute - Franz Clinic
Feb 10, 2022
LUTATHERA Injection General Use Result Survey
Recruiting
- Somatostatin Receptor-positive Neuroendocrine Tumor
- LUTATHERA
-
Kashiwa, Chiba, Japan
- +6 more
Apr 25, 2023
Small Cell Lung Cancer and Breast Cancer Trial in Worldwide (Satoreotide tetraxetan, Satoreotide trizoxetan)
Terminated
- Small Cell Lung Cancer and Breast Cancer
- Satoreotide tetraxetan
- Satoreotide trizoxetan
-
Houston, Texas
- +7 more
Aug 22, 2022
Advanced Lung Carcinoid Tumor, Functioning Lung Carcinoid Tumor, Locally Advanced Lung Neuroendocrine Tumor Trial in Boston,
Recruiting
- Advanced Lung Carcinoid Tumor
- +11 more
- Everolimus
- Lutetium Lu 177 Dotatate
-
Boston, Massachusetts
- +1 more
Jul 19, 2022
Effectiveness and Outcomes Associated With Lutathera Treatment
Active, not recruiting
- Gastroenteropancreatic Neuroendocrine Tumor
-
Alessandria, Italy
- +17 more
May 4, 2022
Neuroendocrine Tumors, Lung Neuroendocrine Tumor, Thymus Tumors Trial in France, Italy, Spain (177Lu-edotreotide, Everolimus)
Not yet recruiting
- Neuroendocrine Tumors
- +2 more
-
Bourdeaux, France
- +24 more
Jun 23, 2023
Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor Trial in Madison (Single Photon Emission Computed
Not yet recruiting
- Neuroendocrine Tumors
- Somatostatin Receptor-positive Neuroendocrine Tumor
- Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)
- +3 more
-
Madison, WisconsinUniversity of Wisconsin - Madison
Nov 2, 2023
Advanced Gastroenteropancreatic Neuroendocrine Tumor Trial (Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide,
Not yet recruiting
- Advanced Gastroenteropancreatic Neuroendocrine Tumor
- Lutetium (177Lu) Oxodotreotide Injection;long-acting Octreotide
- long-acting Octreotide.
- (no location specified)
May 22, 2023
Neuroendocrine Tumors Trial in China (Lutetium[177Lu] Oxodotreotide Injection, Octreotide LAR)
Not yet recruiting
- Neuroendocrine Tumors
- Lutetium[177Lu] Oxodotreotide Injection
- Octreotide LAR
-
Beijing, Beijing, China
- +20 more
Jul 25, 2022
Metastatic Neuroendocrine Tumor Trial (Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate)
Not yet recruiting
- Metastatic Neuroendocrine Tumor
- Biospecimen Collection
- +4 more
- (no location specified)
Feb 10, 2023
NSCLC, EGF-R Positive NSCLC Trial in Shanghai (Furmonertinib)
Recruiting
- NSCLC
- EGF-R Positive Non-Small Cell Lung Cancer
-
Shanghai, Shanghai, ChinaShanghai General Hospital
Jan 12, 2022
Neuroendocrine Tumors Trial in Worldwide (177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine
Recruiting
- Neuroendocrine Tumors
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT
- +4 more
-
Palo Alto, California
- +30 more
Dec 14, 2022
Neuroendocrine Tumors Trial in Edmonton ([68]Ga-HA-DOTATATE)
Recruiting
- Neuroendocrine Tumors
-
Edmonton, Alberta, CanadaCross Cancer Institute
Jun 18, 2021
Carcinoma, Neuroendocrine Trial in Edmonton ([177]Lu-DOTA-TATE)
Recruiting
- Carcinoma, Neuroendocrine
-
Edmonton, Alberta, CanadaCross Cancer Institute
Apr 12, 2021
Adult Medulloblastoma, Childhood Medulloblastoma, Neuroblastoma Trial in Iowa City (drug, procedure, radiation)
Completed
- Adult Medulloblastoma
- +4 more
- gallium Ga 68-edotreotide
- +4 more
-
Iowa City, IowaUniversity of Iowa Hospitals and Clinics
Aug 26, 2021